<DOC>
	<DOCNO>NCT00068913</DOCNO>
	<brief_summary>Patients MELAS syndrome experience devastate mental impairment . This study evaluate effectiveness drug dichloroacetate ( DCA ) reduce symptom MELAS .</brief_summary>
	<brief_title>Evaluating Effectiveness Dichloroacetate MELAS Syndrome</brief_title>
	<detailed_description>Although many organ system affect mitochondrial ( mt ) DNA point mutation , nervous system particularly vulnerable . Maternally inherited mtDNA point mutation may cause chronic progressive encephalopathy mental retardation . Patients MELAS ( mitochondrial myopathy , encephalopathy , lactic acidosis , stroke-like episode ) syndrome A3243G point mutation elevate brain lactate level . Research show lactic acidosis associate progressive impairment patient MELAS . This study evaluate effectiveness DCA lower lactate level slow progression MELAS . Patients A3243G mitochondrial mutation either stroke seizure enrol study . Patients randomize receive either DCA placebo . At predetermined time point , patient receive DCA switch placebo patient receive placebo switch DCA . Patients study visit every 3 month 3 year . Study visit include neurological exam , cognitive testing , nerve conduction test , MRIs . Study medicine , test , hospitalization research purpose , travel expense fully cover study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>MELAS Syndrome</mesh_term>
	<criteria>Inclusion Criteria A3243G mtDNA point mutation maternally related someone mutation Symptomatic MELAS , include previous seizure stroke Certain laboratory value Ability comply study protocol</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2004</verification_date>
	<keyword>Lactic Acidosis</keyword>
	<keyword>Mitochondrial Disorder</keyword>
	<keyword>Stroke</keyword>
	<keyword>Seizure</keyword>
</DOC>